Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Mirabegron”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00410514
What this trial is testing

Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)

Who this might be right for
Lower Urinary Tract SymptomsBladder Outlet Obstruction
Astellas Pharma Inc 200
Early research (Phase 1)Study completedNCT04476966
What this trial is testing

Bioequivalence Study of Mirabegron From Bladogra 25 mg Extended Release Tablets (Multi-Apex for Pharmaceutical Industries, Egypt) Versus Myrbetriq 25 mg Extended Release Tablets (Marketed by Astellas Pharma US, Inc, Product of Japan)

Who this might be right for
Healthy
Genuine Research Center, Egypt 29
Post-approval studies (Phase 4)UnknownNCT05188742
What this trial is testing

Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial

Who this might be right for
Overactive Bladder Syndrome
Taipei Veterans General Hospital, Taiwan 180
Testing effectiveness (Phase 2)UnknownNCT03600766
What this trial is testing

Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study

Who this might be right for
BPHErectile DysfunctionProstate Hyperplasia+2 more
Mansoura University 50
Large-scale testing (Phase 3)Study completedNCT00662909
What this trial is testing

Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

Who this might be right for
Urinary Bladder, Overactive
Astellas Pharma Inc 2,149
Early research (Phase 1)Study completedNCT02127034
What this trial is testing

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects

Who this might be right for
Healthy SubjectsPharmacokineticsDrug-Drug Interaction (DDI)
Astellas Pharma Europe B.V. 26
Not applicableStudy completedNCT07018934
What this trial is testing

Alfuzosin and Mirabegron for Double-J Stent Symptoms

Who this might be right for
Ureteral Stent-Related Symptoms
University of Gaziantep 100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05713799
What this trial is testing

Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity

Who this might be right for
Insulin ResistanceObesity
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 60
Testing effectiveness (Phase 2)Study completedNCT01604928
What this trial is testing

Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder

Who this might be right for
Urinary Bladder, Overactive
Astellas Pharma Europe B.V. 260
Testing effectiveness (Phase 2)Ended earlyNCT02462837
What this trial is testing

Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement

Who this might be right for
Urinary Bladder, OveractivePainLower Urinary Tract Symptoms
Southern Illinois University 11
Large-scale testing (Phase 3)UnknownNCT03044912
What this trial is testing

Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

Who this might be right for
Overactive Bladder Syndrome
Buddhist Tzu Chi General Hospital 574
Post-approval studies (Phase 4)Looking for participantsNCT05051436
What this trial is testing

The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics

Who this might be right for
Pre-diabetesObesity
Philip Kern 96
Post-approval studies (Phase 4)Study completedNCT02086188
What this trial is testing

Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Theodore R. Brown, MD MPH 28
Post-approval studies (Phase 4)Study completedNCT07533565
What this trial is testing

A Pilot Study of Mirabegron and Montelukast in Cirrhotic Patients

Who this might be right for
CirrhosisAsthma
Kafrelsheikh University 78
Post-approval studies (Phase 4)Active Not RecruitingNCT06465576
What this trial is testing

Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry)

Who this might be right for
Urinary Incontinence in Children
University of Aarhus 216
Post-approval studies (Phase 4)Study completedNCT02536976
What this trial is testing

Mirabegron in Parkinson Disease and Impaired Cognition

Who this might be right for
Parkinson DiseaseOveractive BladderImpaired Cognition
HealthPartners Institute 7
Post-approval studies (Phase 4)Study completedNCT03558919
What this trial is testing

Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder

Who this might be right for
Overactive Bladder
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh 81
Early research (Phase 1)Study completedNCT00939757
What this trial is testing

Study of the Effect of Food on the Pharmacokinetics of Mirabegron

Who this might be right for
HealthyPharmacokinetics of Mirabegron
Astellas Pharma Inc 76
Early research (Phase 1)Study completedNCT05992428
What this trial is testing

Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults

Who this might be right for
Healthy
Dong-A ST Co., Ltd. 37
Testing effectiveness (Phase 2)Study completedNCT02916693
What this trial is testing

Mirabegron For Erectile Dysfunction

Who this might be right for
Erectile DysfunctionOveractive BladderUrinary Incontinence
Johns Hopkins University 20
Next Page